1 prilosec 1 label comprehension studies 02255 and12179 karen lechter, j.d., ph.d. fda division of...

24
1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office of Drug Safety

Upload: colleen-poole

Post on 23-Dec-2015

216 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

1

Prilosec 1 Label Comprehension Studies 02255 and12179

Karen Lechter, J.D., Ph.D.

FDA

Division of Surveillance, Research, and Communication Support

Office of Drug Safety

Page 2: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

2

Overview

• Purpose of label comprehension studies• 2 Prilosec 1 label comprehension studies

– Study 02255--general pop./self-selection– Study 12179--appropriate use by special

populations

• Issues about which we have concerns• Implications for label

Page 3: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

3

21 CFR 330.10 (a) (4) (v)

OTC labels must be

…likely to be read and understood by the ordinary individual, including individuals of low comprehension, under customary conditions of purchase and use.

Page 4: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

4

Study 02255: Participants

N=684: 43% male; 57% female

1. General population (N=297)

Frequent HB sufferers 2. low literate (<8th gr. reading level; N=162)

3. high literate (N=155)

4. HB sufferers taking drugs listed on label as requiring MD advice (N=96)

5. Pregnant or nursing HB sufferers (N=42)

Page 5: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

5

Study 02255--Product Purpose

Product Purpose (open-ended question)

HighResponse Gen.pop. Lit. Low

Lit.

Prevent frequent HB 39% 39% 36%

Page 6: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

6

Study 02255--Episodic Use

• 3 questions about acute episodic relief– range 48%-55% correct (general cohort)

• 2 questions about acute episodic prevention– range 54%-61% correct (general cohort)

Page 7: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

7

Study 02255--Self-Selection

Subgroup Correct/Acceptable

Had labeled symptoms (85) 41%

Used labeled meds (96) 50%

After brand names 82%

Page 8: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

8

Study 02255--Self-Selection: Those who should not use or

should consult MD

Subgroup Correct/Acceptable

Total: should not use (659) 67%

Non HB (137) 80% Infreq. HB (92) 76%

Allergic to product (7) 86%

HB preg./nursing (42) 91%

continued...

Page 9: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

9

Study 02255--Applying the Label to Self and Others

• Self-selection questions suggest problem applying label to self

• Scenario responses about use with listed medications or medical conditions suggest good understanding but may be artifact

Page 10: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

10

Conclusion--Study 02255

The tested label failed to convey adequately that Prilosec is not for episodic use– It is not for acute HB symptoms– It is not for prevention of meal-

induced HB

Page 11: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

11

Conclusion--Study 02255

• It is not clear if consumers can apply the label well to their own situation if they require physician consultation because– They are using medicines listed on the

label, or– They have health conditions listed on the

label

Page 12: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

12

More Data Needed

Further testing would help determine if the proposed label works better.

Page 13: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

13

Study 12179: Purpose

Do consumers with medical conditions requiring physician consultation– Understand they must see a physician

before use?– Understand the indication?

– Apply label information correctly about

consulting a doctor before use with certain

medical conditions?

Page 14: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

14

Study 12179: Participants

• N=145: 41% male; 59% female

• Had frequent heartburn

• Had at least 1 condition mentioned on label as requiring physician consultation

• Were not taking medications listed on label as needing physician consultation

Page 15: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

15

Study 12179: Label

Label similar to final proposed label, but listed 6 medications requiring physician consultation, rather than 3

Page 16: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

16

Study 12179: Agency Analysis of Self-Selection Question

• Include only those who should see a physician before use

• Eliminate those 40– Taking Prilosec– With infrequent chest pain or infrequent

wheezing

• Analyze results for the 105 remaining– All should have said they should not use or

would consult a physician

Page 17: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

17

Study 12179: Scoring Differences with Sponsor

• Sponsor scored anyone who had ever discussed their condition listed on label with health care professional as OK to use the product.

• Agency did not score these participants as OK to use

Page 18: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

18

Study 12179: Agency Analysis of Self-Selection Results

Responses N %

Incorrect--would use 56 53%

Correct/Acceptable 47 45%

Ask a doctor 27 26%

Would not use 20 19%

Page 19: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

19

Study 12179: Product Purpose

Response % (N=145)

Prevent frequent HB 32%

Page 20: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

20

Study 12179: Applying the Label to Other People

• Hypothetical question scores in 90%’s– 3 conditions needing physician

consultation– Correct response was to consult doctor

or not use

• 1/3 said person with headache should consult doctor or not use

Page 21: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

21

Label Changes after Label Comprehension Studies

• The label was not changed to improve communication of non-episodic use and prevention only messages.

• List of medications shortened in proposed label from 6 to 3.

• List of medical conditions in proposed label is shorter and more bulleted than in 02255 study, same as in 12179

Page 22: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

22

Conclusions: Studies 02255 and 12179

• Participants understand– Prilosec 1 is for frequent heartburn– Do not use Prilosec 1 if you

• Do not have heartburn• Have infrequent heartburn• Are allergic• Are pregnant or nursing

Page 23: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

23

Conclusions: Studies 02255 and 12179

• Participants understand do not use if– Trouble swallowing– Chest pain with other symptoms– Chronic cough– Black tarry stools– Unexplained weight loss– Under age 18– Heartburn worse with nausea and vomiting

Page 24: 1 Prilosec 1 Label Comprehension Studies 02255 and12179 Karen Lechter, J.D., Ph.D. FDA Division of Surveillance, Research, and Communication Support Office

24

Conclusions

• Consumers believe Prilosec 1 can be used episodically to relieve acute HB symptoms or to prevent meal-induced HB

• Not clear if consumers with medical conditions listed on label or taking medications listed on label would seek medical advice before use or decline to use